Nicorette Lozenge and NicoDerm CQ recall: Superpotent
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK…
Why was Nicorette Lozenge and NicoDerm CQ recalled?
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
What should I do if I have this product?
Review the official FDA enforcement record for current instructions.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.
Which lot codes, UPCs or models are affected?
Lot #13L05N, Expiry: 8/15
- Product
- Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK…
- Recalling firm
- GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
- Quantity
- 150 cases
- Distribution
- U.S. Nationwide
- Recall date
- April 30, 2014
- Classification
- Class III
- Status
- Terminated
- Agency
- FDA (drug)